Clinical Edge Journal Scan

Interstitial lung disease is prevalent in patients with RA and tied to shorter survival


 

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Recommended Reading

No higher risk for surgical site infection following TKA in RA vs. osteoarthritis
MDedge Rheumatology
Flaxseed shows promise as adjuvant therapy in RA
MDedge Rheumatology
Herpes zoster events are common in tofacitinib-treated RA patients but are clinically manageable
MDedge Rheumatology
Circulating biomarkers may aid in screening for cardiac alterations in RA
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: RA January 2022
MDedge Rheumatology
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
MDedge Rheumatology
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
MDedge Rheumatology
Immunological response after SARS-CoV-2 vaccine in rituximab-treated RA patients
MDedge Rheumatology
Fatigue prevalent and persistent even in early RA
MDedge Rheumatology
Pain and functional impairment affect sleep quality in RA
MDedge Rheumatology